InpharmD™





One touch literature search.

So you can spend more time with patients

Ask any clinical question, receive a curated response.

Get Started Free

Trusted by 10,000+ clinical pharmacists.

                           

Play Circle

Learn about InpharmD™ in under 90 seconds

What is InpharmD™?


Literature searching is tedious. InpharmD™ is here to help.

Clinical pharmacists can ask any question, anytime, from anywhere, and we’ll perform a custom literature search.

(And a 32% chance it’s already been asked.)


More than 30 of the world's best health systems hire an InpharmD™ virtual DI pharmacist, yielding:


128,816

Clinical Pharmacist Hours Saved

4x +

ROI

100%

Customer Satisfaction Rate

This is how InpharmD™ transforms LITERATURE.

What's Being Asked...

Which antipsychotics have evidence in PTSD?
Is there any data supporting the use of banana bags (IV fluids + IV thiamine + IV folic acid + IV multivitamin) for p...
What is the data on safety and efficacy of fosfomycin use for UTI treatment in pregnant females?
What is the comparative effect on blood sugar and A1C lowering with empagliflozin at doses 10 mg, 12.5 mg, and 25 mg?
What is the incidence of chest wall rigidity with fentanyl IV push? How does it compare to other opioids?

What would you like to ask InpharmD™?

InpharmD's Answer GPT's Answer

Author:azkaa@inpharmd.com, PharmD, BCPS + InpharmD™ AI LEARN MORE 

The evidence for antipsychotics in post-traumatic stress disorder (PTSD) is limited and inconsistent, largely based on small, short-duration studies. Risperidone is the most studied agent, showing modest symptom improvement versus placebo in some trials, mainly as adjunctive therapy, but with inconsistent findings and no clear benefit in selective serotonin reuptake inhibitors (SSRI)-resistant PTSD. Olanzapine has mixed results, with some trials reporting symptom or sleep improvements and oth...

The 2023 Veterans Affairs Department of Defense (VA/DoD) guidelines on management of post-traumatic stress disorder (PTSD) suggests against the use of any antipsychotic, including aripiprazole, asenapine, brexpiprazole, cariprazine, iloperidone, lumateperone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, or ziprasidone, for augmentation of medications for PTSD, citing very low-quality evidence, small sample sizes, inconsistent efficacy, and a risk-benefit profile in which well-established harms outweigh uncertain benefits. Evidence reviewed showed that risperidone, aripiprazole, and olanzapine were the only agents studied as augmentation, and none demonstrated consistent or statistically significant improvement in overall PTSD outcomes compared with placebo. The 2018 National Institute for Health and Care Excellence (NICE) similarly states that antipsychotics are not first-line treatments for PTSD and should not be considered alternatives to trauma-focused psycholog...

READ MORE→

A search of the published medical literature revealed 2 studies investigating the researchable question:

Which antipsychotics have evidence in PTSD?

Level of evidence
C - Multiple studies with limitations or conflicting results  

READ MORE→

[1] Veterans Affairs Department of Defense (VA/DoD). Clinical Practice Guideline for Management of Posttraumatic Stress Disorder and Acute Stress Disorder. Published 2023. Accessed January 15, 2026. https://www.healthquality.va.gov/HEALTHQUALITY/guidelines/MH/ptsd/VA-DoD-CPG-PTSD-Full-CPG-Edited-111624-V5-81825.pdf
[2] National Institute for Health and Care Excellence (NICE). Post-traumatic stress disorder. Published December 2018. Accessed January 15, 2026.
[3] Berger W, Mendlowicz MV, Marques-Portella C, et al. Pharmacologic alternatives to antidepressants in posttraumatic stress disord...

InpharmD's Answer GPT's Answer

Author:, PharmD, BCPS + InpharmD™ AI LEARN MORE 

Available literature does not support routine use of the traditional “banana bag” (intravenous fluids combined with thiamine, folic acid, and multivitamins) for patients with alcohol use disorder, particularly in critically ill settings. Evidence consistently identifies thiamine as the most clinically important deficiency to assess and replace, while standard banana bag formulations may not deliver adequate thiamine to the central nervous system and lack evidence of benefit from multivitamin ...

According to the 2020 American Society of Addiction Medicine (ASAM) Clinical Practice Guideline on Alcohol Withdrawal Management, alcohol withdrawal can cause significant morbidity in patients, particularly those in the critical care setting, and intensive care unit (ICU) admission may warrant prophylactic interventions to reduce the risk of developing withdrawal-related complications. Patients in the ICU should be closely monitored for worsening signs and symptoms, as well as for the development of Wernicke encephalopathy (WE), a potentially severe consequence of thiamine (vitamin B1) deficiency. Traditionally, multivitamin infusions, often referred to as “banana bags,” have been administered to ICU patients to prevent WE. However, studies examining the effectiveness of the standard ICU protocol have suggested that the banana bag approach may not adequately address the risk, particularly when signs and symptoms are masked or mimicked by other illnesses. These findings have led to r...

READ MORE→

A search of the published medical literature revealed 4 studies investigating the researchable question:

Is there any data supporting the use of banana bags (IV fluids + IV thiamine + IV folic acid + IV multivitamin) for patients with alcohol abuse? Specifically for the combination of medications in a banana bag vs IV thiamine alone (or any of the individual agents alone)?

Level of evidence
C - Multiple studies with limitations or conflicting results  

READ MORE→

[1] The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management. J Addict Med. 2020;14(3S Suppl 1):1-72. doi:10.1097/ADM.0000000000000668
[2] Flannery AH, Adkins DA, Cook AM. Unpeeling the Evidence for the Banana Bag: Evidence-Based Recommendations for the Management of Alcohol-Associated Vitamin and Electrolyte Deficiencies in the ICU. Crit Care Med. 2016;44(8):1545-1552. doi:10.1097/CCM.0000000000001659
[3] Shakory S. Thiamine in the management of alcohol use disorders. Can Fam Physician. 2020;66(3):165-166.
[4] Lewis MJ. Alcoholism and nutrition: a review of vitamin suppleme...

InpharmD's Answer GPT's Answer

Author:zophia@inpharmd.com, PharmD, BCPS + InpharmD™ AI LEARN MORE 

Single-dose oral fosfomycin (3 g) is an effective and well-tolerated option for treating lower urinary tract infections and asymptomatic bacteriuria in pregnant women. Available evidence demonstrates clinical and microbiologic cure rates comparable to multi-day courses of nitrofurantoin, β-lactams, sulfonamides, and other antibiotics, with adverse events being mild and primarily gastrointestinal. The 2023 ACOG consensus includes fosfomycin among first-line options, noting its safety in pregna...

A 2023 clinical consensus by the American College of Obstetricians and Gynecologists (ACOG) Committee explored the management of urinary tract infections (UTIs) in pregnant individuals. The panel stated that choice of antibiotic therapy depends not only on culture results but also on susceptibility patterns and safety profiles, and includes nitrofurantoin, β-lactams, sulfonamides, and fosfomycin. Fosfomycin is dosed at 3 grams orally once as part of its treatment regimen. [1] The typical treatment duration for asymptomatic bacteriuria (ASB) is generally 5–7 days, which reflects the standard duration chosen in most studies. Fosfomycin is an exception and has demonstrated good efficacy as a single-dose treatment for ASB and symptomatic acute cystitis, making it a viable option for 1-day treatment. While 3-day treatment courses are recommended and commonly used for acute cystitis in nonpregnant women, there is a lack of studies evaluating a 3-day course for ASB. [1] Additionally,...

READ MORE→

A search of the published medical literature revealed 3 studies investigating the researchable question:

What is the data on safety and efficacy of fosfomycin use for UTI treatment in pregnant females?

Level of evidence
B - One high-quality study or multiple studies with limitations  

READ MORE→

[1] Urinary Tract Infections in Pregnant Individuals. Obstet Gynecol. 2023;142(2):435-445. doi:10.1097/AOG.0000000000005269
[2] Nicolle LE, Gupta K, Bradley SF, et al. Clinical Practice Guideline for the Management of Asymptomatic Bacteriuria: 2019 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2019;68(10):e83-e110. doi:10.1093/cid/ciy1121
[3] Wang T, Wu G, Wang J, et al. Comparison of single-dose fosfomycin tromethamine and other antibiotics for lower uncomplicated urinary tract infection in women and asymptomatic bacteriuria in pregnant women: A systematic review...

InpharmD's Answer GPT's Answer

Author:zophia@inpharmd.com, PharmD, BCPS + InpharmD™ AI LEARN MORE 

Available evidence suggests that empagliflozin provides clinically meaningful reductions in blood glucose and HbA1c at doses of 10 mg and 25 mg, with most analyses demonstrating similar glycemic efficacy between these doses and only small, inconsistent numerical differences favoring 25 mg (Tables 1-11). HbA1c reductions are generally in the range of approximately 0.6–0.8% with both doses, and fasting plasma glucose lowering follows a comparable pattern, indicating a limited dose–response effe...

A 2021 network meta-analysis evaluated the efficacy and safety of empagliflozin at various dosages in patients with type 2 diabetes mellitus (T2DM). The analysis incorporated data from 23 randomized controlled trials involving 10,518 patients. The study aimed to discern the optimal dosing strategy for empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, widely used for its cardiovascular benefits and hypoglycemic effects. The comprehensive search spanned eight databases, filtering for studies that compared at least two empagliflozin doses and reported pharmacodynamic and adverse event outcomes. The meta-analysis demonstrated that higher daily doses (10, 25, 50 mg) of empagliflozin were significantly superior in lowering hemoglobin A1c (HbA1c) and fasting plasma glucose (FPG) compared to lower doses (1, 2.5, 5 mg). The 25 mg dose emerged as the most effective in balancing efficacy and safety, particularly after 12 weeks of treatment. The study also highlighted a dose-re...

READ MORE→

A search of the published medical literature revealed 11 studies investigating the researchable question:

What is the comparative effect on blood sugar and A1C lowering with empagliflozin at doses 10 mg, 12.5 mg, and 25 mg?

Level of evidence
A - Multiple high-quality studies with consistent results  

READ MORE→

[1] Wu Q, Liu M, Fang Z, et al. Efficacy and safety of empagliflozin at different doses in patients with type 2 diabetes mellitus: A network meta-analysis based on randomized controlled trials. J Clin Pharm Ther. 2022;47(3):270-286. doi:10.1111/jcpt.13521
[2] Zhang YJ, Han SL, Sun XF, et al. Efficacy and safety of empagliflozin for type 2 diabetes mellitus: Meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018;97(43):e12843. doi:10.1097/MD.0000000000012843

InpharmD's Answer GPT's Answer

Author:Dena Homayounieh, PharmD, BCPS + InpharmD™ AI LEARN MORE 

The incidence of chest wall rigidity (Wooden Chest Syndrome; WCS) following fentanyl injection is not well defined, as most data come from sporadic case reports, but it is generally considered low. WCS appears to be unique to fentanyl and fentanyl analogs, likely related to their high lipophilicity and rapid central nervous system penetration. Potential factors associated with increased incidence include rapid administration, higher doses, extremes of age, and underlying neurologic or metabol...

Published review articles describe Wooden Chest Syndrome (WCS), a combination of chest wall and diaphragm rigidity, often with laryngospasm, as essentially unique to fentanyl and fentanyl analogs. It can occur after intravenous, transdermal, or inhalational administration, with incidence and severity closely related to dose and speed of delivery. Human studies report WCS as a rare but clinically significant complication in perioperative or critical care settings, where it can reduce chest wall compliance, impair spontaneous ventilation, and complicate weaning from mechanical ventilation. Upper airway obstruction due to glottic or supraglottic closure may further contribute to respiratory compromise, highlighting the need for prompt recognition and management. Conversely, traditional opioids such as morphine may produce abdominal wall muscle rigidity at high doses but have not been shown to cause upper airway compromise in humans unless combined with anesthetic gases, and reports of ...

READ MORE→

A search of the published medical literature revealed 2 studies investigating the researchable question:

What is the incidence of chest wall rigidity with fentanyl IV push? How does it compare to other opioids?

Level of evidence
C - Multiple studies with limitations or conflicting results  

READ MORE→

[1] Torralva R, Janowsky A. Noradrenergic Mechanisms in Fentanyl-Mediated Rapid Death Explain Failure of Naloxone in the Opioid Crisis. J Pharmacol Exp Ther. 2019;371(2):453-475. doi:10.1124/jpet.119.258566
[2] Chamoun K, Chevillard L, Hajj A, Callebert J, Mégarbane B. Mechanisms of neurorespiratory toxicity induced by fentanyl analogs—lessons from animal studies. Pharmaceuticals. 2023;16(3):382. doi:10.3390/ph16030382
[3] Joshi GP, Warner DS, Twersky RS, Fleisher LA. A comparison of the remifentanil and fentanyl adverse effect profile in a multicenter phase IV study. J Clin Anesth. 2002;...

Why choose InpharmD™?

Find answers, not documents.

Before InpharmD™


BeforeTime
Your team spends hours per week cobbling together literature from different studies, many behind paywalls, leaving little time for action.
BeforeTime
TI opportunities are discovered (or presented by third parties) months after the fact, resulting in costly missed savings.
BeforeTime
Decisions may be made without a complete picture, or pushed out while gathering consensus.

After InpharmD™


BeforeTime
InpharmD™ delivers customized, actionable drug information in real time, so you can focus on execution.
BeforeTime
Your team stays informed immediately when new data emerges or prices change, and you’ll always be the first to know when any changes impact your formulary.
BeforeTime
With InpharmD™, your team can make faster, more informed decisions and move forward with confidence.

What Clinical Pharmacists Are Saying...


     

Assists in our research and is a great way or us to get an answer to a medical question without spending an average of 2 hours researching UptoDate or PubMed ourselves.


  Jordan C., PharmD, New Jersey

     

Huge time saver with thorough responses.


  Jane D., PharmD, Georgia

     

I’d never heard of a DI pharmacist before, now I have one. In. My. Pocket. Amazing!


     

Holy Shhh. Cow! Holy Cow! These summaries are beautiful.


  Jane D., PharmD, Georgia

     

I just want to say: This is such a brilliant idea! You people are genius.


     

OH MY GOD WHERE HAVE YOU BEEN ALL MY LIFE!


     

I can’t tell you how much time I spend literature searching. And how I CANNOT STAND PAYWALLS. THIS IS UNBELIEVABLE!! (covers face for sec) thank you, thank you, thank you!


     

So they’re basically connecting academic researchers with front line providers and then automating everything. It’s simply brilliant.


     

The clinical pharmacist was our secret weapon anyway. (Smiles wryly) This pharmacist AI seems superhuman. I’m just blown away, honestly. (Looks at camera somberly.)


     

It’s an ENTIRE DI DEPARTMENT, that lives in Epic. Give me a second. I’m just having a hard time wrapping my head around that.


     

Sorry just give me a second, my mind is blown.


     

Stop reading and just download the app already! I’ve tried all of them. This is by far the most advanced, best-in-class.


What would you like to ask InpharmD™?

Sign up for a free trial & start right away.

Get Started Free